Pharma Foods International Co., Ltd. Logo

Pharma Foods International Co., Ltd.

Researches and sells functional ingredients and direct-to-consumer health & beauty products.

2929 | T

Overview

Corporate Details

ISIN(s):
JP3802310007
LEI:
Country:
Japan
Address:
京都市西京区御陵大原1番地49
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pharma Foods International Co., Ltd. develops and sells functional food ingredients and related consumer products. The company operates through two main segments: a functional materials business and a direct-to-consumer (B2C) business. The functional materials division researches and develops unique, science-backed ingredients with a focus on areas such as immunity, aging, and the nervous system. The B2C segment utilizes these proprietary ingredients in its e-commerce and wholesale distribution of supplements, cosmetics, and non-pharmaceutical products. Guided by a mission to create food products with pharmaceutical-like efficacy, the company aims to promote health and improve quality of life, and is also engaged in biomedical drug discovery.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-21 08:34
Registration Form
確認書
Japanese 8.2 KB
2025-10-21 08:32
Annual Report
有価証券報告書-第28期(2024/08/01-2025/07/31)
Japanese 1.4 MB
2025-06-05 08:32
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.2 KB
2025-03-14 05:31
Report Publication Announcement
確認書
Japanese 8.2 KB
2025-03-14 05:30
Interim Report
半期報告書-第28期(2024/08/01-2025/07/31)
Japanese 292.0 KB
2024-11-18 07:36
Share Issue/Capital Change
臨時報告書
Japanese 29.9 KB
2024-10-28 07:43
Registration Form
訂正有価証券届出書(参照方式)
Japanese 50.6 KB
2024-10-28 07:35
Post-Annual General Meeting Information
臨時報告書
Japanese 28.6 KB
2024-10-24 08:35
Registration Form
訂正有価証券届出書(参照方式)
Japanese 51.3 KB
2024-10-24 08:33
Registration Form
確認書
Japanese 8.2 KB
2024-10-24 08:32
Governance Information
内部統制報告書-第27期(2023/08/01-2024/07/31)
Japanese 22.7 KB
2024-10-24 08:30
Annual Report
有価証券報告書-第27期(2023/08/01-2024/07/31)
Japanese 1.4 MB
2024-10-22 07:50
Registration Form
有価証券届出書(参照方式)
Japanese 64.0 KB
2024-06-14 06:03
Report Publication Announcement
確認書
Japanese 8.2 KB
2024-06-14 06:02
Quarterly Report
四半期報告書-第27期第3四半期(2024/02/01-2024/04/30)
Japanese 184.3 KB

Automate Your Workflow. Get a real-time feed of all Pharma Foods International Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pharma Foods International Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pharma Foods International Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.